首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2015年 5期 胰腺疾病 => 肝脏肿瘤 =>抗病毒治疗对HBV相关终末期肝细..
抗病毒治疗对HBV相关终末期肝细胞癌患者生存质量及预后的影响
Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy
文章发布日期:2015年04月15日  来源:  作者:李鹏,翟云,张世斌,等  点击次数:1461次  下载次数:275次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的 探讨HBV相关终末期肝细胞癌(HCC)患者在内科保肝等治疗方案的基础上联合抗HBV治疗的获益情况。方法 收集2011年1月-2012年1月于北京佑安医院就诊的初次诊断乙型肝炎肝硬化基础上的晚期HCC患者105例,根据治疗方案不同分为常规治疗组(A组,n=44)和抗病毒治疗组(B组,n=61),随访96周,通过Karnofsky评分、Child-Pugh评分、MELD评分及生存率的比较,评价患者受益情况。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验,预后分析采用Kaplan-Meier生存分析。结果随访至治疗24周时,B组患者的一般情况及肝功能与A组相比改善明显,Karnofsky评分明显提高(t=4.785,P=0.031),Child-Pugh评分明显降低(t=5.015,P=0.028);至96周时,B组患者Karnofsky评分(t=8.578,P=0.016)、Child-Pugh评分(t=6.774,P=0.021)、MELD评分(t=9.014,P=0.008)与同期A组患者相比明显改善;随访96周时B组患者生存率显著高于A组,差异具有统计学意义(67.2% vs 45.5%,P=0.026)。结论给予HBV相关终末期HCC患者有效抗病毒治疗能够提高患者生存质量、改善肝功能、减少并发症、延长其生存期,从而使患者获益。
【Abstract】:ObjectiveTo investigate the acquired benefit of antiviral therapy in addition to routine treatment regimen including hepatoprotective internal medicine in patients with hepatitis B virus (HBV)-related end-stage hepatocellular carcinoma (HCC). MethodsA total of 105 end-stage HCC patients who were admitted to our hospital from January 2011 to January 2012 with an initial diagnosis of hepatitis B cirrhosis were included in this study. According to the treatment regimen, the patients were divided into routine treatment group (group A) and antiviral therapy group (group B). Patients were followed up for 96 weeks, and the benefit of antiviral therapy was evaluated by comparison of Karnofsky score, Child-Push score, Model for End-Stage Liver Disease (MELD) score, and survival rate between two groups. Comparison of continuous data between groups was made by t test, and comparison of categorical data was made by χ2 test. Prognostic analysis was made by Kaplan-Meier survival analysis. ResultsAt week 24 of follow-up, patients in group B had markedly improved general status and liver function, significantly increased Karnofsky score (t=4.785, P=0.031), and significantly reduced Child-Push score (t=5.015, P=0.028) compared with those in group A. At week 96, the Karnofsky score, Child-Push score, and MELD score all showed significant improvements in group B compared with those in group A (t=8.578, P=0.016; t=6.774, P=0.021; t=9.014, P=0.008). The patients in group B had a significantly higher survival rate than those in group A (67.2% vs 45.5%, P=0.026). ConclusionEffective antiviral therapy in patients with HBV-related end-stage HCC could improve the quality of life and liver function, reduce complications, prolong the survival time, and thus bring great benefits to those patients.
【关键字】:肝炎病毒,乙型;癌,肝细胞;预后
【Key words】:hepatitis B virus; carcinoma, hepatocellular; prognosis
【引证本文】:

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号